– Public comment period now open until May 31st; Requests to make oral comment during public meeting also being accepted – BOSTON, May 4, 2018 – The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of elagolix (AbbVie/Neurocrine Biosciences) for the management of endometriosis and associated […]
–Open Input now being accepted until January 8, 2018– BOSTON, December 14, 2017 – The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of elagolix (AbbVie) for management of endometriosis with associated pain. The FDA’s decision on whether to approve elagolix is expected during the second quarter of 2018. An […]
Upcoming Appearances Key Dates February 16th: CTAF meeting to discuss ICER’s MS report in Oakland, CA Read the Evidence Report here
In all our reports, we strive to include the patient perspective at every step of the process. Our reports benefit from informative, productive conversations about the issues that really matter to patients. When patients are involved, our reports become infinitely more comprehensive, actionable, and accurate. During development of our psoriasis report, we were lucky to […]
Upcoming Appearances November 1, 2016: Matt Seidner, CTAF Program Manager, will present ICER’s report on diabetes prevention programs at the Massachusetts Department of Public Health’s Diabetes Prevention Summit in Westborough, MA. November 4, 2016: Dan Ollendorf, PhD, ICER’s Chief Scientific Officer, will participate in a panel on integrating value-based assessment into alternative financing options at […]
Upcoming Appearances October 5th-6th: Steven Pearson, MD, MSc, ICER’s President, will present at the Express Scripts Labor Advisory Council October 20th: Midwest CEPAC Meeting in St. Louis, MO Key Dates October 6th: Revised Scoping Document for Abuse-Deterrent Opioids October 28th: Evidence Report for Psoriasis In Case You Missed It In addition to those we mentioned […]
We’re busy here at ICER! To keep you up to date, here are a few of our upcoming conference appearances and key report milestones for the next month. And since we never rest, we’ve also included an update on our website where we’ve made some changes to make it easier track of all of our […]
Update: ICER’s report on RA will now be the subject of a New England CEPAC meeting scheduled for March 23, 2017. The timeline has been revised accordingly. For the current timeline and meeting details, please see the meeting page. July 11, 2016 – The Institute for Clinical and Economic Review (ICER) will develop a report assessing […]
The Institute for Clinical and Economic Review (ICER) has released the slate of new drugs it plans to review in 2016. These reviews are a continuation of the new drug assessment program begun in the Fall of 2015. The list of drugs to be reviewed is based on ICER’s discussion with multiple payers and other […]
The Institute for Clinical and Economic Review (ICER) has released the slate of new drugs it plans to review in 2016. These reviews are a continuation of the new drug assessment program begun in the Fall of 2015. The list of drugs to be reviewed is based on ICER’s discussion with multiple payers and other […]